BRPI0415923A - uso de antagonistas de neuroquinina no tratamento de incontigência urinária - Google Patents

uso de antagonistas de neuroquinina no tratamento de incontigência urinária

Info

Publication number
BRPI0415923A
BRPI0415923A BRPI0415923-3A BRPI0415923A BRPI0415923A BR PI0415923 A BRPI0415923 A BR PI0415923A BR PI0415923 A BRPI0415923 A BR PI0415923A BR PI0415923 A BRPI0415923 A BR PI0415923A
Authority
BR
Brazil
Prior art keywords
treatment
urinary incontinence
neurokinin antagonists
antagonists
urinary
Prior art date
Application number
BRPI0415923-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul William Glue
Kevin Hall Mcallister
Eckhard Weber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0415923A publication Critical patent/BRPI0415923A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI0415923-3A 2003-10-27 2004-10-26 uso de antagonistas de neuroquinina no tratamento de incontigência urinária BRPI0415923A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51479103P 2003-10-27 2003-10-27
PCT/EP2004/012081 WO2005039563A2 (en) 2003-10-27 2004-10-26 Use of neurokinin antagonists in the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
BRPI0415923A true BRPI0415923A (pt) 2006-12-26

Family

ID=34520229

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415923-3A BRPI0415923A (pt) 2003-10-27 2004-10-26 uso de antagonistas de neuroquinina no tratamento de incontigência urinária

Country Status (9)

Country Link
US (1) US7776851B2 (enExample)
EP (2) EP2158910A1 (enExample)
JP (1) JP2007509184A (enExample)
CN (1) CN1874766A (enExample)
AU (1) AU2004283038B9 (enExample)
BR (1) BRPI0415923A (enExample)
CA (1) CA2543552A1 (enExample)
MX (1) MXPA06004688A (enExample)
WO (1) WO2005039563A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0593559A1 (en) * 1991-07-05 1994-04-27 MERCK SHARP & DOHME LTD. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
FR2700472B1 (fr) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6664253B2 (en) * 2000-10-17 2003-12-16 Boehringer Ingelheim Pharma Kg Neurokinin antagonists
WO2002051440A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
JP4175113B2 (ja) 2001-03-14 2008-11-05 小野薬品工業株式会社 Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤
MXPA04006571A (es) * 2002-01-18 2004-10-04 Kyorin Seiyaku Kk Derivado de pirimidina biciclica fusionada.
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
CA2479277A1 (en) * 2002-03-26 2003-10-02 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
KR20040099367A (ko) * 2002-03-26 2004-11-26 교린 세이야꾸 가부시키 가이샤 타키키닌 수용체 길항제로서의 축합 바이사이클릭 피리딘 유도체

Also Published As

Publication number Publication date
US7776851B2 (en) 2010-08-17
AU2004283038A1 (en) 2005-05-06
CA2543552A1 (en) 2005-05-06
JP2007509184A (ja) 2007-04-12
EP1686985A2 (en) 2006-08-09
AU2004283038B9 (en) 2008-04-24
AU2004283038B2 (en) 2008-01-31
US20070149504A1 (en) 2007-06-28
EP2158910A1 (en) 2010-03-03
WO2005039563A2 (en) 2005-05-06
CN1874766A (zh) 2006-12-06
WO2005039563A3 (en) 2005-06-30
MXPA06004688A (es) 2006-07-05

Similar Documents

Publication Publication Date Title
BR0316375A (pt) Diazinopirimidinas
SE0302811D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
BR0309873A (pt) Pirazolo-pirimidin-4-onas substituìdas
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
GB0128996D0 (en) Organic compounds
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
ATE365740T1 (de) Substituierte pyrazolopyrimidine
PT1506185E (pt) Compostos novos e sua utilizacao
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
SE0401762D0 (sv) Novel compounds
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
TW200604197A (en) New compounds
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
BRPI0407913A (pt) antagonistas receptores de ccr-3
SE0101038D0 (sv) Novel compounds
BRPI0416873A (pt) derivados de benzoxazina e usos dos mesmos
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
TW200635917A (en) Novel compounds
SE0303280D0 (sv) Novel compounds
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
SE0403086D0 (sv) Compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.